Concepedia

Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan

Pin‐Nan Cheng, Lein‐Ray Mo, Chun‐Ting Chen, Chi-Yi Chen, Chung‐Feng Huang, Hsing‐Tao Kuo, Kuo‐Chih Tseng, Yi‐Hsiang Huang, Chi‐Ming Tai, Cheng‐Yuan Peng,

Infectious Diseases and Therapy · 2021 · 27 citations · 29 references

DOIFull text

Open access

Abstract

SOF/VEL was highly effective and well tolerated in Taiwanese patients, irrespective of viral genotype, liver disease severity, and comorbidities.

References

29

Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis

Bart J. Veldt, Jordan J. Feld, Heiner Wedemeyer et al. · JAMA · 2012 · 1.5K citations · Full text

EASL recommendations on treatment of hepatitis C: Final update of the series☆

Jean–Michel Pawlotsky, Francesco Negro, Alessio Aghemo et al. · Journal of Hepatology · 2020 · 1.2K citations

, , +6

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

Kris V. Kowdley, Stuart C. Gordon, K. Rajender Reddy et al. · New England Journal of Medicine · 2014 · 1.1K citations · Full text

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

Jordan J. Feld, Ira M. Jacobson, Christophe Hézode et al. · New England Journal of Medicine · 2015 · 1.1K citations · Full text

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

Graham R. Foster, Nezam H. Afdhal, Stuart K. Roberts et al. · New England Journal of Medicine · 2015 · 845 citations · Full text